<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01941589</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-13-0401-OH-CTIL</org_study_id>
    <nct_id>NCT01941589</nct_id>
  </id_info>
  <brief_title>Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis</brief_title>
  <official_title>Combination Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of steroids in the treatment of ulcerative Colitis (UC) is well established, and
      recommended by professional societies. However, there are no data investigating whether the
      addition and/or continuation of 5-aminosalicylic agents as combination therapy with systemic
      corticosteroids is superior to corticosteroids alone in patients with moderate-severe active
      UC. Thus, in practical terms, the decision regarding 5-aminosalicylic (to add or continue),
      on top of steroids treatment, is taken on an arbitrary basis. The aim of this study is to
      compare the efficacy of steroids alone Vs combination of steroids + 5-aminosalicylic in the
      treatment of moderate-severe UC exacerbation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      he role of steroids in the treatment of ulcerative Colitis (UC) is well established, and
      recommended by professional societies. However, there are no data investigating whether the
      addition and/or continuation of 5-aminosalicylic agents as combination therapy with systemic
      corticosteroids is superior to corticosteroids alone in patients with moderate-severe active
      UC. Thus, in practical terms, the decision regarding 5-aminosalicylic (to add or continue),
      on top of steroids treatment, is taken on an arbitrary basis. The aim of this study is to
      compare the efficacy of steroids alone Vs combination of steroids + 5-aminosalicylic in the
      treatment of moderate-severe UC exacerbation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of patients who respond to the treatment</measure>
    <time_frame>day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the percentage of patients in need of a rescue medication</measure>
    <time_frame>day 5, 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>colectomy rate</measure>
    <time_frame>1 month, 3 months post randomization</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>duration of hospitalization</measure>
    <time_frame>3-90</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>present 5-ASA arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-ASA naive arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>present 5-ASA arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV corticosteroids only / PO Methylprednisolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-ASA naive arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV corticosteroids only / PO Methylprednisolone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone</intervention_name>
    <description>maximal oral 5-ASA+/-topical 5-ASA+IV corticosteroids</description>
    <arm_group_label>present 5-ASA arm 1</arm_group_label>
    <arm_group_label>5-ASA naive arm 1</arm_group_label>
    <other_name>rafassal</other_name>
    <other_name>pentasa</other_name>
    <other_name>asacol</other_name>
    <other_name>hydrocortisone</other_name>
    <other_name>solu-cortef</other_name>
    <other_name>methylprednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>corticosteroids only</intervention_name>
    <description>IV corticosteroids only</description>
    <arm_group_label>present 5-ASA arm 2</arm_group_label>
    <arm_group_label>5-ASA naive arm 2</arm_group_label>
    <other_name>hydrocortisone</other_name>
    <other_name>solu-cortef</other_name>
    <other_name>methylprednisolone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  UC known and diagnosed by established clinical-endoscopic and histological criteria or
             newly-diagnosed UC, based on clinical and endoscopic findings, and about to start
             treatment with corticosteroids.

          -  current hospitalization with severe Ulcerative Colitis exacerbation as defined by a
             Lichtiger score of &gt;10

          -  age &gt;18

          -  if taking thiopurines, the dose must be stable for 2 months prior to admission

        Exclusion Criteria:

          -  pregnant women

          -  allergy/unable to take study medications

          -  active infection

          -  severe renal/liver/cardiorespiratory condition

          -  toxic megacolon or signs of imminent colectomy

          -  treatment with an anti-tumor necrosis factor in 3 months prior to admission

          -  prior treatment with cyclosporin or tacrolimus

          -  alcohol dependancy

          -  unwilling/ unable to give an informed consent

          -  participation in clinical trials in the last 2 months prior to admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ofir Har-Noy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center, Tel-Hashomer, ISRAEL 52621</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ofir Har-Noy, MD</last_name>
    <phone>+972-3-530-2679</phone>
    <email>ofirharnoy@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shomron Ben-Horin, MD</last_name>
    <phone>+972-3-530-2679</phone>
    <email>sben-horin@013net.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>6th affiliated hospital of Sun yat-sen university</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Tang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology and Hepatology,The First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mao Ren, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Gastrologie-Entérologie-Hépatologie, Centre Hospitalier Universitaire de Saint-Étienne</name>
      <address>
        <city>Saint-Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Roblin, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology Venizeleio General Hospital, Leoforos Knosou</name>
      <address>
        <city>Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantinos Karmiris, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, University Hospital &amp; Medical School of Ionnina</name>
      <address>
        <city>Ioánnina</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantinos Katsanos, MD PHD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastroenterology department, Soroka medical center</name>
      <address>
        <city>Be'er Sheva`</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doron schwartz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel HaShomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ofir Har-Noy, MD</last_name>
      <phone>+972-3-530-2679</phone>
      <email>ofirharnoy@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ofir Har-Noy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università di Roma Sapienza</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Cesarini, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>nstitute of Gastroenterology and Department of Internal Medicine, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae-Hee Cheon, MD PHD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zvezdara University Clinical Center, Gastroenterology Department</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marijana Protic, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>France</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Serbia</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2013</study_first_submitted>
  <study_first_submitted_qc>September 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2013</study_first_posted>
  <last_update_submitted>October 21, 2017</last_update_submitted>
  <last_update_submitted_qc>October 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Ofir Harnoy MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Mesalamine</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Aminosalicylic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

